Ensysce Biosciences Inc.

ENSC | NASDAQ

Price Alert Chart Builder DCF Calculator

$0.49

-$0.03 (-5.02%)

Sep 11, 2026, 4:00 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-5.02%

(1D)

Rating

Updated: Aug 7, 2026

31.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $7.48M

1D Range

0.48 0.52

52W Range

0.23 2.75

Valuation (TTM)

PE -0.19

PB -9.57

EV/EBITDA -0.56

Valuation (NTM)

Forward PE N/A

Forward PEG N/A

Price Target N/A

Cash Flow

FCF Yield -120.0%

SBC Adj. FCF Yield -121.0%

SBC Impact -0.8%

Margins

Gross Margin 100.0%

Operating Margin -1087.5%

FCF Margin -771.2%

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 32.4% | -162.1%

FCF 3Y | 5Y 18.6% | -107.2%

Returns

ROA -426.9%

ROE -1532.3%

ROIC 1385.3%

Financial Health

Net Cash

$479.86K

Current Ratio 0.70

Interest Coverage -791.64

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the Unit...

Sector Healthcare

Industry Biotechnology

Employees 7

IPO Date Mar 13, 2018

Website www.ensysce.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Latest Earnings

Aug 13, 2026

EPS

-$0.20

Miss 0.00%

YoY: +74.68%

REV

$1.2M

Miss 0.00%

Next Earnings

Nov 13, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞